Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (NCT04246047)
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Yuma, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (69 Sites)
Showing the first 25 of 69 sites.
- GSK Investigational Site — Yuma, Arizona
- GSK Investigational Site — Denver, Colorado
- GSK Investigational Site — Kansas City, Kansas
- GSK Investigational Site — Fairfield, Ohio
- GSK Investigational Site — Tyler, Texas
- GSK Investigational Site — Liverpool, New South Wales
- GSK Investigational Site — Wollongong, New South Wales
- GSK Investigational Site — Benowa, Queensland
- GSK Investigational Site — Brussels,
- GSK Investigational Site — Brussels,
- GSK Investigational Site — Ghent,
- GSK Investigational Site — Roeselare,
- GSK Investigational Site — Beijing,
- GSK Investigational Site — Jinan,
- GSK Investigational Site — Shenyang,
- GSK Investigational Site — Alexandroupoli,
- GSK Investigational Site — Athens,
- GSK Investigational Site — Thessaloniki,
- GSK Investigational Site — Tel Aviv,
- GSK Investigational Site — Bergamo,
- GSK Investigational Site — Meldola FC,
- GSK Investigational Site — Milan,
- GSK Investigational Site — Siena,
- GSK Investigational Site — Aichi,
- GSK Investigational Site — Aichi,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.